Literature DB >> 22762785

Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.

Floortje Mols1, Simone Oerlemans, Allert H Vos, Ad Koster, Silvia Verelst, Pieter Sonneveld, Lonneke V van de Poll-Franse.   

Abstract

BACKGROUND: This prospective population-based study describes health-related quality of life (HRQOL) and disease-specific complaints of patients with multiple myeloma (MM) up to 10 yr post-diagnosis.
METHODS: The Eindhoven Cancer Registry was used to select all patients diagnosed with MM from 1999 to 2010. Patients with MM completed the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires at baseline (n = 156; 74% response rate) and 1 yr later (n = 80). The EORTC QLQ-C30 was also completed by an age- and sex-matched normative population (n = 500).
RESULTS: Patients with MM reported statistically significant and clinically relevant worse scores on all EORTC QLQ-C30 scales (all P's at least < 0.01) compared to the norm. Also, patients with MM reported a mean decrease (e.g., worsening) between baseline and 1-yr follow-up scores for: quality of life (mean, 68 vs. 55, respectively, P < 0.001; 74% of patients had a deteriorated score), fatigue (33 vs. 39, P < 0.05; 50%), nausea and vomiting (6.3 vs. 13, P < 0.05; 71%), pain (33 vs. 43, P < 0.05; 59%), and dyspnea (17 vs. 33, P < 0.001; 66%). The most bothering symptoms during the past week were tingling hands/feet (32%), back pain (28%), bone aches/pain (26%), pain in arm/shoulder (19%), and feeling drowsy (18%). Also, 37% worried about their future health, 34% thought about their disease, and 21% worried about dying.
CONCLUSION: Patients with MM experience a very high symptom burden and low HRQOL. Future studies should focus on possible mechanisms that can predict low HRQOL and high symptom burden in patients with MM and should investigate optimal ways to alleviate these.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22762785     DOI: 10.1111/j.1600-0609.2012.01831.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  43 in total

1.  Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage.

Authors:  Erin E Kent; Anita Ambs; Sandra A Mitchell; Steven B Clauser; Ashley Wilder Smith; Ron D Hays
Journal:  Cancer       Date:  2014-11-04       Impact factor: 6.860

2.  Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.

Authors:  Kevin W Song; Meletios A Dimopoulos; Katja C Weisel; Philippe Moreau; Antonio Palumbo; Andrew Belch; Stephen Schey; Pieter Sonneveld; Lars Sternas; Xin Yu; Ramesh Amatya; Mara S Monzini; Mohamed Zaki; Christian Jacques; Jesus San Miguel
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

3.  Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program.

Authors:  Lene Kongsgaard Nielsen; Rikke Faebo Larsen; Lene Jarlbaek; Sören Möller; Eva Jespersen
Journal:  Ann Hematol       Date:  2021-01-06       Impact factor: 3.673

4.  Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.

Authors:  Thomas van Gelder; Brendan Mulhern; Dounya Schoormans; Olga Husson; Richard De Abreu Lourenço
Journal:  Qual Life Res       Date:  2020-01-14       Impact factor: 4.147

5.  Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry.

Authors:  Olga Husson; Floortje Mols; Lonneke van de Poll-Franse; Jolanda de Vries; Goof Schep; Melissa S Y Thong
Journal:  Support Care Cancer       Date:  2015-01-06       Impact factor: 3.603

6.  Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review.

Authors:  Francesco Sparano; Michele Cavo; Pasquale Niscola; Tommaso Caravita; Fabio Efficace
Journal:  Support Care Cancer       Date:  2018-03-20       Impact factor: 3.603

7.  Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.

Authors:  R Baz; H M Lin; A-M Hui; R D Harvey; K Colson; K Gallop; P Swinburn; J Laubach; D Berg; P Richardson
Journal:  Support Care Cancer       Date:  2015-02-24       Impact factor: 3.603

8.  Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Authors:  Michel Delforge; Leonard Minuk; Jean-Claude Eisenmann; Bertrand Arnulf; Letizia Canepa; Alberto Fragasso; Serge Leyvraz; Christian Langer; Yousef Ezaydi; Dan T Vogl; Pilar Giraldo-Castellano; Sung-Soo Yoon; Charles Zarnitsky; Martine Escoffre-Barbe; Bernard Lemieux; Kevin Song; Nizar Jacques Bahlis; Shien Guo; Mara Silva Monzini; Annette Ervin-Haynes; Vanessa Houck; Thierry Facon
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

9.  Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry.

Authors:  Floortje Mols; Olga Husson; Jan-Anne Roukema; Lonneke V van de Poll-Franse
Journal:  J Cancer Surviv       Date:  2013-05-16       Impact factor: 4.442

10.  Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.

Authors:  A J M Beijers; G Vreugdenhil; S Oerlemans; M Eurelings; M C Minnema; C M Eeltink; L V van de Poll-Franse; F Mols
Journal:  Support Care Cancer       Date:  2015-12-03       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.